Alpha-ENaC RNAi Agents with Integrin Ligands for Pulmonary Delivery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current RNAi agents for inhibiting alpha-ENaC gene expression have limitations, including short duration of action and on-target toxicity, and there is a need for novel RNAi agents that can selectively and efficiently reduce ENaC activity to treat diseases associated with enhanced ENaC activity, such as cystic fibrosis and chronic obstructive pulmonary disease.
Innovation Solution
Development of novel alpha-ENaC-specific RNAi agents comprising sense and antisense strands, 16 to 30 nucleotides in length, with core stretches showing at least 85% identity to alpha-ENaC mRNA, designed to target specific positions on the alpha-ENaC gene, and conjugated with integrin targeting ligands for enhanced delivery to epithelial cells.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If inhaled small molecule ENaC inhibitors are used, then initial promise in treatment of CF is achieved, but short duration of action and on-target toxicity (hyperkalemia) occur
Solution Approach 1:
The patent changes the chemical parameters of the inhibitor by using RNAi agents (small interfering RNA) instead of small molecules. This fundamental parameter change allows for prolonged duration of action through stable RNA-protein complexes and reduced renal clearance, while the specificity of RNAi reduces off-target effects causing hyperkalemia
Solution Approach 2:
The patent employs composite structures by conjugating RNAi agents with cell-penetrating peptides and protective moieties. This composite approach enhances cellular uptake, protects the RNAi agent from degradation, and extends duration of action while maintaining treatment effectiveness
2Reliability
If inhaled small molecule ENaC inhibitors are used, then initial promise in treatment of CF is achieved, but on-target toxicity (hyperkalemia) occurs
Solution Approach 1:
The patent changes the molecular class from small molecules to RNAi agents, which provide superior target specificity through sequence complementarity. This parameter change eliminates hyperkalemia by preventing inadvertent inhibition of renal ENaC channels while maintaining effective inhibition of pulmonary ENaC
Solution Approach 2:
The patent applies local quality by designing RNAi agents with specific sequence targets that distinguish pulmonary ENaC from renal ENaC. The localized action at the pulmonary epithelium, enhanced by inhalation delivery and cell-penetrating peptides, ensures treatment effectiveness without systemic toxicity
3Productivity
If RNAi agents are designed with core stretches showing at least 85% identity to alpha-ENaC mRNA, then selective and efficient inhibition is achieved, but specificity requirements increase
Solution Approach 1:
The patent optimizes the identity parameter by requiring at least 85% sequence identity between the RNAi agent core stretch and alpha-ENaC mRNA. This parameter threshold balances high inhibition efficiency with practical manufacturability, allowing for effective silencing while accommodating standard RNA synthesis tolerances
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The described RNAi agents effectively inhibit alpha-ENaC gene expression, reducing ENaC activity and providing therapeutic benefits for respiratory and ocular diseases by selectively targeting and reducing ENaC levels, offering improved duration of action and reduced toxicity compared to existing treatments.
Implementation Method 1
RNA interference (RNAi) agents, e.g., double stranded RNAi agents, for inhibition of alpha-ENaC gene expression
Data Source
AI summary
Described are RNAi agents, compositions that include RNAi agents, and methods for inhibition of an alpha-ENaC (SCNN1A) gene. The alpha-ENaC RNAi agents and RNAi agent conjugates disclosed herein inhibit the expression of an alpha-ENaC gene. Pharmaceutical compositions that include one or more alpha-ENaC RNAi agents, optionally with one or more additional therapeutics, are also described. Delivery of the described alpha-ENaC RNAi agents to epithelial cells, such as pulmonary epithelial cells, in vivo, provides for inhibition of alpha-ENaC gene expression and a reduction in ENaC activity, which can provide a therapeutic benefit to subjects, including human subjects.